Medigene AG Shares Plunge to New Depths Amid Ongoing Restructuring

Medigene AG operates under insolvency administration, with shares at €0.025 and leadership changes. Its future hinges on administrator decisions.

The biotechnology firm Medigene AG continues to operate under court-appointed insolvency administration nearly a year after filing, with its equity telling a stark story of distress. While research into immunotherapies persists on paper, the harsh realities of the restructuring process are reflected in the company's market valuation.

Leadership and Operational Shifts Under Administration

Significant changes have swept through the company's executive suite during this critical period. Former CEO Selwyn Ho departed in July 2025 upon the conclusion of his contract. His successor, Ralph Schäfer, previously served as the company's chief legal counsel and now manages operations. All activities, including the ongoing development of TCR-based therapies, proceed under the direct supervision of insolvency administrator Axel W. Bierbach.

The company's journey through insolvency began with an application in April 2025, followed by the formal court order to open proceedings in August of that year.

A Deteriorating Market Position

The trading environment for Medigene's investors has transformed dramatically. The share price has collapsed to a mere €0.025, marking a severe decline of almost 20 percent in recent trading. This erosion in value underscores the evaporating market confidence in a shareholder-positive outcome from the proceedings.

Further compounding its challenges, the stock no longer trades on the Xetra electronic platform, where activity has been suspended for approximately a year. Concurrently, its listing was downgraded from the regulated Prime Standard segment to the General Standard on the Frankfurt exchange, which is subject to less stringent requirements.

High-Risk Speculation with an Uncertain Future

For current and potential investors, the equity now represents an exceptionally high-risk speculative instrument. The continuation of research operations does little to alter the immediate reality that shares trading at a few cents are purely speculative. The future trajectory of Medigene hinges entirely on forthcoming decisions by the insolvency administrator, which will determine whether any residual value can be salvaged from the company's remaining assets.